Medtronic Book Value Per Share Growth & History (MDT)
Medtronic's book value per share was $38.64 for fiscal 2026.
View full Medtronic company overviewMedtronic annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-24 | $38.64 | $1.18 | +3.14% |
| 2025 | 2025-04-25 | $37.46 | -$0.83 | −2.17% |
| 2024 | 2024-04-26 | $38.29 | -$0.39 | −1.02% |
| 2023 | 2023-04-28 | $38.69 | -$0.80 | −2.04% |
| 2022 | 2022-04-29 | $39.49 | $1.26 | +3.31% |
| 2021 | 2021-04-30 | $38.23 | $0.39 | +1.04% |
| 2020 | 2020-04-24 | $37.83 | $0.47 | +1.26% |
| 2019 | 2019-04-26 | $37.36 | -$0.09 | −0.24% |
| 2018 | 2018-04-27 | $37.45 | $0.79 | +2.15% |
| 2017 | 2017-04-28 | $36.66 | -$0.55 | −1.48% |
| 2016 | 2016-04-29 | $37.21 | -$0.23 | −0.61% |
| 2015 | 2015-04-24 | $37.44 | $17.98 | +92.38% |
| 2014 | 2014-04-25 | $19.46 | $1.15 | +6.25% |
| 2013 | 2013-04-26 | $18.32 | — | — |
Medtronic quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-07-31 | $39.24 | $1.88 | +5.03% |
| Q4 2026 | 2026-04-24 | $38.64 | $1.18 | +3.14% |
| Q3 2026 | 2026-01-31 | $38.17 | -$0.32 | −0.82% |
| Q3 2026 | 2026-01-23 | $38.17 | -$0.32 | −0.82% |
| Q2 2026 | 2025-10-24 | $37.95 | $0.14 | +0.37% |
| Q1 2026 | 2025-07-25 | $37.36 | -$0.02 | −0.06% |
| Q4 2025 | 2025-04-25 | $37.46 | -$0.83 | −2.17% |
| Q3 2025 | 2025-01-24 | $38.49 | -$0.47 | −1.20% |
| Q2 2025 | 2024-10-25 | $37.81 | -$0.88 | −2.26% |
| Q1 2025 | 2024-07-26 | $37.39 | -$1.08 | −2.81% |
| Q4 2024 | 2024-04-26 | $38.29 | -$0.39 | −1.02% |
| Q3 2024 | 2024-01-26 | $38.95 | $0.29 | +0.74% |
| Q2 2024 | 2023-10-27 | $38.69 | -$0.32 | −0.81% |
| Q1 2024 | 2023-07-28 | $38.47 | -$1.16 | −2.93% |
| Q4 2023 | 2023-04-28 | $38.69 | -$0.80 | −2.04% |
| Q3 2023 | 2023-01-27 | $38.67 | -$0.47 | −1.20% |
| Q2 2023 | 2022-10-28 | $39.00 | $0.34 | +0.89% |
| Q1 2023 | 2022-07-29 | $39.62 | $1.34 | +3.49% |
| Q4 2022 | 2022-04-29 | $39.49 | $1.26 | +3.31% |
| Q3 2022 | 2022-01-28 | $39.14 | $1.47 | +3.89% |
| Q2 2022 | 2021-10-29 | $38.66 | $1.38 | +3.69% |
| Q1 2022 | 2021-07-30 | $38.29 | $0.85 | +2.26% |
| Q4 2021 | 2021-04-30 | $38.23 | $0.39 | +1.04% |
| Q3 2021 | 2021-01-29 | $37.67 | -$0.97 | −2.51% |
| Q2 2021 | 2020-10-30 | $37.28 | -$0.45 | −1.20% |
| Q1 2021 | 2020-07-31 | $37.44 | -$0.12 | −0.32% |
| Q4 2020 | 2020-04-24 | $37.83 | $0.47 | +1.26% |
| Q3 2020 | 2020-01-24 | $38.64 | $1.47 | +3.96% |
| Q2 2020 | 2019-10-25 | $37.73 | $0.88 | +2.40% |
| Q1 2020 | 2019-07-26 | $37.56 | $0.41 | +1.09% |
| Q4 2019 | 2019-04-26 | $37.36 | -$0.09 | −0.24% |
| Q3 2019 | 2019-01-25 | $37.17 | $0.10 | +0.28% |
| Q2 2019 | 2018-10-26 | $36.85 | -$1.17 | −3.09% |
| Q1 2019 | 2018-07-27 | $37.16 | -$0.25 | −0.67% |
| Q4 2018 | 2018-04-27 | $37.45 | $0.79 | +2.15% |
| Q3 2018 | 2018-01-26 | $37.07 | $0.99 | +2.74% |
| Q2 2018 | 2017-10-27 | $38.02 | $1.47 | +4.03% |
| Q1 2018 | 2017-07-28 | $37.41 | $0.63 | +1.71% |
| Q4 2017 | 2017-04-28 | $36.66 | -$0.55 | −1.48% |
| Q3 2017 | 2017-01-27 | $36.08 | -$0.19 | −0.53% |
| Q2 2017 | 2016-10-28 | $36.55 | -$0.62 | −1.67% |
| Q1 2017 | 2016-07-29 | $36.78 | -$0.58 | −1.55% |
| Q4 2016 | 2016-04-29 | $37.21 | -$0.23 | −0.61% |
| Q3 2016 | 2016-01-29 | $36.27 | $36.30 | — |
| Q2 2016 | 2015-10-30 | $37.17 | — | — |
| Q1 2016 | 2015-07-31 | $37.36 | — | — |
| Q4 2015 | 2015-04-24 | $37.44 | — | — |
| Q3 2015 | 2015-01-23 | -$0.03 | — | — |
Medtronic book value per share trends
Over the last five fiscal years, Medtronic's book value per share increased from $38.23 to $38.64, a change of $0.41. The latest reported quarter, Q1 2027, shows $39.24.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...